Page last updated: 2024-12-06

1-methyladenosine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

1-methyladenosine (m1A) is a naturally occurring nucleoside modification found in RNA. It is formed by the methylation of the N1 position of adenosine. m1A is a common modification in both tRNA and rRNA, where it plays a role in regulating translation and ribosome function. It is also found in mRNA, where it has been implicated in regulating mRNA stability, translation efficiency, and splicing. m1A is of great interest to researchers due to its potential role in various biological processes. Studies are exploring the mechanisms by which m1A is synthesized and recognized by cellular machinery, as well as its role in regulating gene expression and cellular function.'

Cross-References

ID SourceID
PubMed CID27476
CHEMBL ID1866485
CHEBI ID16020
SCHEMBL ID19553541
MeSH IDM0042731

Synonyms (24)

Synonym
CHEBI:16020 ,
(2r,3s,4r,5r)-2-(hydroxymethyl)-5-(6-imino-1-methyl-purin-9-yl)tetrahydrofuran-3,4-diol
adenosine, n,6-didehydro-1,6-dihydro-1-methyl-
1-methyladenosine ,
C02494
NCGC00163305-01
nsc 92165
adenosine, 1-methyl- (van)
n(1)-methyladenosine
GFYLSDSUCHVORB-IOSLPCCCSA-N
adenosine, n,6-didehydro-1,9-dihydro-1-methyl-
CHEMBL1866485
AC-32347
(2r,3s,4r,5r)-2-(hydroxymethyl)-5-(6-imino-1-methyl-6,9-dihydro-1h-purin-9-yl)oxolane-3,4-diol
AKOS030241121
SCHEMBL19553541
HY-113081
CS-0059513
(2r,3s,4r,5r)-2-(hydroxymethyl)-5-(6-imino-1-methyl-1h-purin-9(6h)-yl)tetrahydrofuran-3,4-diol
DTXSID30864632
Q161643
H10051
1-methyl ado
PD018070
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
methyladenosine
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
regulator of G-protein signaling 4Homo sapiens (human)Potency0.94660.531815.435837.6858AID504845
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (9)

Assay IDTitleYearJournalArticle
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1430043Cytotoxicity against PEK cells after 24 hrs2017Bioorganic & medicinal chemistry letters, 03-01, Volume: 27, Issue:5
New tools in nucleoside toolbox of tick-borne encephalitis virus reproduction inhibitors.
AID1430042Antiviral activity against TEBV Absettarov infected in PEK cells assessed as inhibition of viral reproduction preincubated with virus for 1 hr followed by addition to PEK cells measured after 1 hr by gentian violet staining based plaque reduction assay2017Bioorganic & medicinal chemistry letters, 03-01, Volume: 27, Issue:5
New tools in nucleoside toolbox of tick-borne encephalitis virus reproduction inhibitors.
AID1430041Antiviral activity against TEBV Absettarov infected in PEK cells assessed as inhibition of viral reproduction at 50 uM preincubated with virus for 1 hr followed by addition to PEK cells measured after 1 hr by gentian violet staining based plaque reduction2017Bioorganic & medicinal chemistry letters, 03-01, Volume: 27, Issue:5
New tools in nucleoside toolbox of tick-borne encephalitis virus reproduction inhibitors.
AID1430044Cytotoxicity against PEK cells after 7 days2017Bioorganic & medicinal chemistry letters, 03-01, Volume: 27, Issue:5
New tools in nucleoside toolbox of tick-borne encephalitis virus reproduction inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (105)

TimeframeStudies, This Drug (%)All Drugs %
pre-199016 (15.24)18.7374
1990's19 (18.10)18.2507
2000's10 (9.52)29.6817
2010's39 (37.14)24.3611
2020's21 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 31.04

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index31.04 (24.57)
Research Supply Index4.69 (2.92)
Research Growth Index5.08 (4.65)
Search Engine Demand Index37.86 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (31.04)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews9 (8.33%)6.00%
Case Studies0 (0.00%)4.05%
Observational1 (0.93%)0.25%
Other98 (90.74%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]